Literature DB >> 14691156

Impact of bilateral visual impairment on health-related quality of life: the Blue Mountains Eye Study.

Ee-Munn Chia1, Jie Jin Wang, Elena Rochtchina, Wayne Smith, Robert R Cumming, Paul Mitchell.   

Abstract

PURPOSE: To assess the impact of visual impairment on health-related quality of life (HRQOL) in an older population and compare it with the impact of major medical conditions.
METHODS: Participants of the second cross-sectional Blue Mountains Eye Study (BMES; n = 3509; mean age, 66.7 years; 57% female) were asked to complete the self-administered 36-item Short-Form health survey (SF-36), a comprehensive interview, and an eye examination. Visual impairment was defined as visual acuity less than 20/40 (better eye).
RESULTS: Of 3154 (89.9%) participants with complete data, 172 (5.5%) had visual impairment due to refractive errors (correctable visual impairment) and 66 (2.1%) due to eye conditions (noncorrectable visual impairment; 49 mild, 9 moderate, 8 severe). After adjustment for demographic and medical confounders, there was a trend toward lower SF-36 scores in participants with noncorrectable impairment than in those with correctable impairment (physical component score [PCS] Ptrend = 0.01 and mental component score [MCS] Ptrend = 0.02). Increasingly severe noncorrectable visual impairment was associated with significantly poorer SF-36 scores in all but two dimensions. The impact of noncorrectable visual impairment was comparable to that from major medical conditions (e.g., stroke) and had a greater impact on mental than physical domains (mean MCS = 46.2, PCS = 41). No significant differences in HRQOL were demonstrated between visual impairment cases caused by age-related maculopathy and cataract, after adjusting for severity of visual impairment.
CONCLUSIONS: Noncorrectable visual impairment was associated with reduced functional status and well-being, with a magnitude comparable to major medical conditions. These data have implications for disability weights such as those developed by the Global Burden of Disease study.

Entities:  

Mesh:

Year:  2004        PMID: 14691156     DOI: 10.1167/iovs.03-0661

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  87 in total

1.  Increased mortality risk among the visually impaired: the roles of mental well-being and preventive care practices.

Authors:  D Diane Zheng; Sharon L Christ; Byron L Lam; Kristopher L Arheart; Anat Galor; David J Lee
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-14       Impact factor: 4.799

2.  Impact of photodynamic therapy on quality of life of patients with age-related macular degeneration in Korea.

Authors:  Jinhyun Kim; Hyung Woo Kwak; Won Ki Lee; Ha Kyoung Kim
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

3.  [Monotherapy of exudative age-related macular degeneration with ranibizumab in patients at cardiovascular risk. Advantages of ranibizumab compared to a combination with pegaptanib].

Authors:  E Matthé; D Sandner
Journal:  Ophthalmologe       Date:  2011-04       Impact factor: 1.059

4.  Prevalence of refractive error in the United States, 1999-2004.

Authors:  Susan Vitale; Leon Ellwein; Mary Frances Cotch; Frederick L Ferris; Robert Sperduto
Journal:  Arch Ophthalmol       Date:  2008-08

5.  Psychosocial adaptation status and health-related quality of life among older Chinese adults with visual disorders.

Authors:  Chong-Wen Wang; Cecilia L W Chan
Journal:  Qual Life Res       Date:  2009-06-28       Impact factor: 4.147

6.  Visual functioning and quality of life among the older people in Hong Kong.

Authors:  Jason C S Leung; Timothy C Y Kwok; Dicken C C Chan; Kay W K Yuen; Anthony W L Kwok; Dicky T K Choy; Edith M C Lau; P C Leung
Journal:  Int J Geriatr Psychiatry       Date:  2011-09-15       Impact factor: 3.485

Review 7.  The suprachoroidal space as a route of administration to the posterior segment of the eye.

Authors:  Bryce Chiang; Jae Hwan Jung; Mark R Prausnitz
Journal:  Adv Drug Deliv Rev       Date:  2018-03-12       Impact factor: 15.470

8.  Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration.

Authors:  C Hopley; G Salkeld; P Mitchell
Journal:  Br J Ophthalmol       Date:  2004-08       Impact factor: 4.638

9.  Quality of life in the Iranian Blind War Survivors in 2007: a cross-sectional study.

Authors:  Reza Amini; Hamid Haghani; Mehdi Masoumi
Journal:  BMC Int Health Hum Rights       Date:  2010-08-21

10.  The quality of life impact of peripheral versus central vision loss with a focus on glaucoma versus age-related macular degeneration.

Authors:  Keith Evans; Simon K Law; John Walt; Patricia Buchholz; Jan Hansen
Journal:  Clin Ophthalmol       Date:  2009-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.